

REMARKS

In the Office Communication mailed on October 8, 2003, the Examiner alleges that the reply filed on July 15, 2003 is not fully responsive to the prior Office Action because Applicants allegedly change the claimed invention from diagnosis of Alzheimers disease to diagnosis of insulin resistance. The Examiner states that none of the originally filed claims recite the insulin resistance diagnostic markers as amended, thus the Examiner has not entered the reply filed July 15, 2003 in the record of the prosecution of the instant application.


The Examiner appears to have overlooked the Supplemental Preliminary Amendment filed by facsimile on April 29, 2002 in which Applicants amended Claim 2 to replace "Alzheimers disease" with "insulin resistance".

No new matter is added by this amendment. The recitation of "Alzheimers disease" in the originally filed claim was merely a typographical error. Page 46, lines 4-10 of the originally filed specification clearly indicates that the claimed biopolymer markers are related to insulin resistance and not related to Alzheimers disease.

CONCLUSION

Now that Applicants have fully clarified the disease condition to which the claimed biopolymer markers relate, entry and consideration of the Amendment filed on July 15, 2003 is respectfully requested.

Respectfully submitted,



Ferris H. Lander
Registration # 43,377

McHale & Slavin, P.A.
2855 PGA Boulevard
Palm Beach Gardens, FL 33410
(561) 625-6575 (Voice)
(561) 625-6572 (Fax)

\\Ns2\DRV_E\STAFF DATA FILES\Ferris Lander's Files\FL\AMENDMNT.PAT\2132_100_SupplAM1.wpd